Comprehensive Cancer Library

Canakinumab, marketed under the brand name Ilaris, is an advanced biologic medicine used to treat several rare autoinflammatory diseases. For patients living with conditions such as Cryopyrin-Associated Periodic Syndromes (CAPS), Familial Mediterranean Fever (FMF), Still’s disease and recurrent gout flares, this targeted therapy can significantly improve disease control and quality of life. However, because Canakinumab […]

Kineret (anakinra) is an interleukin-1 receptor antagonist (a protein that blocks proinflammatory signals by binding to interleukin-1 receptors) used in the treatment of Rheumatoid Arthritis (RA), Cryopyrin-Associated Periodic Syndromes (CAPS), and Deficiency of Interleukin-1 Receptor Antagonist (DIRA). By targeting a key inflammatory pathway, Kineret helps reduce symptoms and improve disease management in eligible patients. Patients […]

Belzutifan, marketed as Welireg, is an innovative targeted therapy that has transformed treatment options for certain patients with von Hippel-Lindau (VHL) disease–associated tumors and advanced renal cell carcinoma (RCC). As a first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, Belzutifan addresses a critical pathway involved in tumor growth and survival. However, despite its clinical value, access to […]